| Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group F Mosele, J Remon, J Mateo, CB Westphalen, F Barlesi, MP Lolkema, ... Annals of Oncology 31 (11), 1491-1505, 2020 | 918 | 2020 |
| Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer F Mosele, B Stefanovska, A Lusque, AT Dien, I Garberis, N Droin, ... Annals of Oncology 31 (3), 377-386, 2020 | 242 | 2020 |
| Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) R Condorelli, F Mosele, B Verret, T Bachelot, PL Bedard, J Cortes, ... Annals of Oncology 30 (3), 365-373, 2019 | 125 | 2019 |
| Genomics to select treatment for patients with metastatic breast cancer F Andre, T Filleron, M Kamal, F Mosele, M Arnedos, F Dalenc, MP Sablin, ... Nature 610 (7931), 343-348, 2022 | 85 | 2022 |
| Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial F Mosele, E Deluche, A Lusque, L Le Bescond, T Filleron, Y Pradat, ... Nature medicine 29 (8), 2110-2120, 2023 | 77 | 2023 |
| Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study A Bayle, L Belcaid, M Aldea, D Vasseur, F Peyraud, C Nicotra, A Geraud, ... Annals of Oncology 34 (4), 389-396, 2023 | 29 | 2023 |
| Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a … A Bayle, F Peyraud, L Belcaid, M Brunet, M Aldea, R Clodion, P Dubos, ... Annals of Oncology 33 (12), 1328-1331, 2022 | 13 | 2022 |
| Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer F Nguyen Van Long, A Lardy-Cleaud, D Carène, C Rossoni, F Catez, ... BMC cancer 22 (1), 526, 2022 | 12 | 2022 |
| Liquid versus tissue biopsy for detecting actionable alterations according to ESCAT in patients with advanced cancer: A study from the French National Center for Precision … A Bayle, F Peyraud, L Belcaid, M Brunet, M Aldea, R Clodion, P Dubos, ... Annals of Oncology: Official Journal of the European Society for Medical …, 2022 | 10 | 2022 |
| Detection of additional occult malignancy through profiling of ctDNA in late-stage cancer patients M Aldea, L Cerbone, A Bayle, C Parisi, C Sarkozy, D Vasseur, L Verlingue, ... Annals of Oncology 32 (12), 1642-1645, 2021 | 9 | 2021 |
| The influence of cancer molecular subtypes and treatment on the mutation spectrum in metastatic breast cancers B Verret, T Sourisseau, B Stefanovska, F Mosele, A Tran-Dien, F André Cancer Research 80 (15), 3062-3069, 2020 | 9 | 2020 |
| Precision medicine in the era of multi-omics: can the data tsunami guide rational treatment decision? M Aldea, L Friboulet, S Apcher, F Jaulin, F Mosele, T Sourisseau, ... ESMO open 8 (5), 101642, 2023 | 7 | 2023 |
| Natural history and outcome of patients presenting a metastatic breast cancer with PIK3CA mutation F Mosele, B Verret, A Lusque, T Filleron, T Bachelot, M Arnedos, ... Cancer Research 79 (13_Supplement), 4895-4895, 2019 | 3 | 2019 |
| Optimizing the potential of antibody–drug conjugates in oncology F Mosele, G Montagnac, B Pistilli, F Andre Annals of Oncology 34 (11), 964-967, 2023 | 1 | 2023 |
| ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue … D Planchard, N Cozic, M Wislez, C Chouaid, H Curcio, S Cousin, ... Journal of Clinical Oncology 42 (16_suppl), 8501-8501, 2024 | | 2024 |
| Moving toward precision medicine to predict drug sensitivity in patients with metastatic breast cancer M Bottosso, F Mosele, S Michiels, PH Cournède, S Dogan, C Labaki, ... ESMO open 9 (3), 102247, 2024 | | 2024 |
| Trastuzumab deruxtecan for breast cancer: do patients experience a comprehensive benefit? F Mosele, M Di Maio Annals of Oncology 34 (7), 567-568, 2023 | | 2023 |
| Precision Medicine in Breast Cancer Must Consider Target Actionability F Andre, T Filleron, M Kamal, F Mosele, M Arnedos, F Dalenc cancer, 2022 | | 2022 |
| Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers F Mosele, J Remon, J Mateo, CB Westphalen, F Barlesi, MP Lolkema, ... | | 2020 |
| PIK3CA-Mutation beim metastasierten Mammakarzinom F Mosele breast cancer 31, 377-386, 2020 | | 2020 |
